Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial - Choy, EH; Isenberg, DA; Garrood, T (Arthritis Rheum, 2002)
et al.